Related Experiment Videos
Content and activity of cAMP response element-binding protein regulate platelet-derived growth factor receptor-alpha
Peter A Watson1, Charles Vinson, Albina Nesterova
1Denver Research Institute, Denver Veterans Affairs Medical Center, University of Colorado Health Sciences Center, 1055 Clermont Street, Denver, CO 80220, USA.
Abstract:
Experiments in vascular smooth muscle cells (SMCs) indicate that the transcription factor cAMP response element-binding protein (CREB), the cyclic nucleotide response element-binding protein, suppresses expression of the platelet-derived growth factor-alpha receptor gene (PDGFRalpha). Adenovirus-mediated expression of constitutively active CREB mutants decreases PDGFRalpha mRNA, PDGFRalpha protein, and PDGFRalpha promoter-luciferase reporter activity in cultured SMCs. Expression of dominant negative CREB protein, A-CREB, increases PDGFRalpha protein content and the PDGFRalpha-promoter activity in SMCs. Active CREB prevents activation of PDGFRalpha promoter-luciferase reporter activity by CCAAT/enhancer-binding protein-delta (C/EBPdelta), shown to mediate IL-1beta stimulation of PDGFRalpha expression. Exposure of cultured SMCs to high glucose or reactive oxidant stress, which decrease CREB protein content and activity, increases PDGFRalpha protein content and promoter activity. Expression of active CREB blunts reactive oxidant stress-induced PDGFRalpha accumulation in SMCs. Loss of CREB protein in aortic walls of rats with streptozotocin-induced diabetes is accompanied by an increase in PDGFRalpha content. In Ob/Ob mice (which demonstrate reduced aortic wall CREB content vs. Ob/- controls), treatment with the peroxisomal proliferator-activated receptor gamma rosiglitazone increases CREB content and decreases PDGFRalpha content in the aortic wall. Thus, both in vitro and in vivo loss of CREB content and activity and subsequent accumulation of PDGFRalpha may contribute to SMC activation during diabetes.
Insights
The transcription factor CREB suppresses PDGFRalpha expression in smooth muscle cells. Loss of CREB activity, seen in diabetes, increases PDGFRalpha, potentially driving cell activation.
Area of Science:
- Vascular biology
- Molecular endocrinology
- Cellular signaling
Background:
- Vascular smooth muscle cell (SMC) activation is implicated in diabetes.
- Platelet-derived growth factor-alpha receptor (PDGFRalpha) plays a role in SMC function.
- The transcription factor cAMP response element-binding protein (CREB) regulates gene expression.
Purpose of the Study:
- To investigate the role of CREB in regulating PDGFRalpha expression in SMCs.
- To determine if CREB's function is altered in diabetes-related conditions.
- To explore CREB's impact on SMC activation.
Main Methods:
- Adenovirus-mediated gene expression of CREB mutants in cultured SMCs.
- Reporter gene assays to measure PDGFRalpha promoter activity.
- In vivo studies using diabetic rat models and Ob/Ob mice.
Main Results:
- Active CREB suppressed PDGFRalpha mRNA, protein, and promoter activity.
- Loss of CREB function (high glucose, oxidant stress, diabetes) increased PDGFRalpha.
- Rosiglitazone treatment increased CREB and decreased PDGFRalpha in diabetic mouse aortas.
Conclusions:
- CREB acts as a suppressor of PDGFRalpha gene expression in SMCs.
- Reduced CREB activity in diabetes contributes to PDGFRalpha accumulation.
- CREB dysfunction and PDGFRalpha upregulation may drive SMC activation in diabetes.